Roivant Sciences (ROIV) CEO Eric Venker Buys $770K of Stock

Eric Venker, President and CEO of Immunovant, part of Roivant Sciences Ltd. (NasdaqGS: ROIV), made a significant investment in the company by purchasing 200,000 shares on June 24, 2026. The shares were bought at an average price of $3.85 each, totaling an investment of $770,000. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Roivant Sciences Ltd.

Eric Venker was active in trading Roivant Sciences shares around June 24, 2026. On that date, he bought 200,000 shares at $3.85 each. Additionally, Venker sold 200,000 shares at $33.16 in a planned transaction, and another 200,000 shares with no price disclosed. Other insider activities included Chief Accounting Officer Jennifer Humes selling 3,582 shares at $31.43, and CFO Richard Pulik selling 2,129 shares at the same price, both on June 20, 2026.

Other Institutional Activity in Roivant Sciences

Institutional investors have also been active with Roivant Sciences. FMR LLC grew its holdings by 12,201,789 shares, reaching a total of 77,981,253 shares valued at approximately $2.16 billion. Morgan Stanley reduced its position by 6,531,228 shares, ending with 51,828,325 shares worth about $1.44 billion. BlackRock, Inc. added 3,083,785 shares, bringing its total to 44,254,260 shares valued at $1.23 billion. Meanwhile, UBS Group AG increased its stake by 4,228,680 shares, totaling 22,619,472 shares worth $626.6 million. Vanguard Capital Management LLC opened a new position with 20,680,572 shares valued at $572.9 million.

Roivant Sciences Ltd. Stock Up 0.1%

On Saturday, shares of Roivant Sciences Ltd. traded near $34.02 on the NasdaqGS. The company has a market capitalization of approximately $24.47 billion. Although it is not currently profitable, it has a forward P/E ratio of -21.82 and a beta of 1.137, indicating some market volatility. The stock's 52-week range is between $10.71 and $34.68, with a 50-day moving average of $29.46 and a 200-day moving average of $23.96.

Analysts Set New Price Targets

Several analysts have maintained their ratings on Roivant Sciences. On May 26, 2026, Guggenheim maintained a 'buy' rating with a $36.00 price target. Citigroup and TD Cowen also maintained 'buy' ratings with targets of $42.00 and $41.00, respectively, on May 21, 2026. The consensus among analysts is a 'strong buy,' with a mean price target of $39.04 based on 12 analyst opinions.

About Roivant Sciences Ltd.

Roivant Sciences Ltd. is a biopharmaceutical company based in London, United Kingdom, focusing on developing medicines and technologies. Founded in 2014, it operates in the biotechnology sector. The company, led by CEO Mr. Matthew Gline, employs 721 people and has several clinical product candidates, including IMVT-1402 and mosliciguat, targeting various autoimmune and cardiopulmonary diseases.

Bottom Line

Eric Venker's recent purchase of Roivant Sciences shares reflects his confidence in the company's future. Investors closely watch insider transactions like these to gauge the outlook of company leaders. As always, it's important to remember that insider transactions are reported after they occur and may not reflect the current position.